This study evaluates the clinical activity of sotorasib (AMG 510), a KRAS G12C inhibitor in stage IV NSCLC tumors with KRAS G12C mutation and <1% PD-L1 and/or LKB1 co-mutation in need of first line treatment. This evidence concerns the gene KRAS and non-small cell lung carcinoma.